k0706
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02629692)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase V-ABLINHIBITOR
ABL inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- k0706
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03996460 | Phase 2 | Jul 31, 2019 | Georgetown University, SPARC |
| NCT03655236 | Phase 2 | Oct 31, 2018 | SPARC |
| NCT03445338 | Phase 1 | Apr 15, 2018 | SPARC |
| NCT03316820 | Phase 1 | Jan 22, 2017 | SPARC |
| NCT02970019 | Phase 2 | Jan 1, 2017 | SPARC |
| NCT02629692 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2016 | SPARC |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SPARC | For profit | 6 | 5 | 2 | 2016 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1